Objective: To examine the effect of outcomes-based pricing on the cost-effectiveness of PCSK9 inhibitors among eligible patients with ASCVD.
Methods and Findings: We used the Cardiovascular Disease Policy Model to estimate the cost-effectiveness of PCSK9 inhibitors among 8.9 million U.S. adults aged 40 to 84 years with ASCVD and low-density lipoprotein cholesterol levels of at least 1.81 mmol/L (70 mg/dL) despite statin therapy. This model is an established state-transition Markov model that uses epidemiologic, clinical trial, registry, and claims data to project the clinical and economic burden of cardiovascular disease among U.S. adults (details are available in the Supplement and Supplement Tables 1 to 6 [available at http://tiny .ucsf.edu/CVDpolicymodel]).